A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease

• Published in: Clinical gastroenterology and hepatology Vol. 20; no. 11; pp. 2462 - 2473.e10
• Main Authors: Toh, Jonathan Zhi Kai, Pan, Xin-Hui, Tay, Phoebe Wen Lin, Ng, Cheng Han, Yong, Jie Ning, Xiao, Jieling, Koh, Jin Hean, Tan, En Ying, Tan, Eunice Xiang Xuan, Dan, Yock Young, Loh, Poay Huan, Foo, Roger, Chew, Nicholas W.S., Sanyal, Arun J., Muthiah, Mark D., Siddiqui, Mohammad Shadab
• Format: Journal Article
• Language: English
• Published: 01.11.2022
• ISSN: 1542-3565; 1542-7714
• DOI: 10.1016/j.cgh.2021.09.021

BACKGROUND & AIMSCardiovascular disease remains the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Studies examining the association of coronary heart disease (CHD) and NAFLD are cofounded by various cardiometabolic factors, particularly diabetes and body mass index. Hence, we seek to explore such association by investigating the global prevalence, independent risk factors, and influence of steatosis grade on manifestation of CHD among patients with NAFLD. METHODSTwo databases, Embase and Medline, were utilized to search for articles relating to NAFLD and CHD. Data including, but not limited to, continent, diagnostic methods, baseline characteristics, prevalence of CHD, CHD severity, NAFLD severity, and risk factors were extracted. RESULTSOf the 38 articles included, 14 reported prevalence of clinical coronary artery disease (CAD) and 24 subclinical CAD. The pooled prevalence of CHD was 44.6% (95% confidence interval [CI], 36.0%-53.6%) among 67,070 patients with NAFLD with an odds ratio of 1.33 (95% CI, 1.21%-1.45%; P < .0001). The prevalence of CHD was higher in patients with moderate to severe steatosis (37.5%; 95% CI, 15.0%-67.2%) than those with mild steatosis (29.6%; 95% CI, 13.1%-54.0%). The pooled prevalence of subclinical and clinical CAD was 38.7% (95% CI, 29.8%-48.5%) and 55.4% (95% CI, 39.6%-70.1%), respectively. CONCLUSIONSteatosis was found to be related with CHD involvement, with moderate to severe steatosis related to clinical CAD. Early screening and prompt intervention for CHD in NAFLD are warranted for holistic care in NAFLD.